

ATARI (ATR inhibitor in combination with olaparib in gynaecological cancer with ARID1A loss)-

A Phase II Proof of Concept Study to assess the Activity of an Ataxia Telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a Single Agent and in Combination with Olaparib in *ARID1A* Stratified Gynaecological Cancers

CI: Susana Banerjee, Royal Marsden and ICR

NCRI

Clear cell cohort (ARID1A loss and no loss)
Endometrioid, carcinosarcoma, cerix

**Awaiting CRUK endorsement
Planned to open end Q1 2019**



ATARI Trial Design

Min 40 – Max 116 patients

Notes: trial is based on an optimal Simon two-stage design for each cohort, with $p_0=10\%$, $p_1=30\%$, one-sided alpha 0.05 and 80% power. In all cohorts, therapy continues until progression or withdrawal from study.

Primary endpoint: Objective Response Rate (RECIST v1.1)

